Online pharmacy giant PharmEasy, which withdrew its IPO last year, is now planning to raise funds through a rights issue to repay a loan. The company aims to raise approximately Rs 2,400 crore at a 90% discount on its stock price. According to sources, the funds will be used to repay a loan from Goldman Sachs, a leading global investment bank.
PharmEasy breached a significant loan term set by Goldman Sachs when it failed to close a Rs 1,000 crore funding round, as reported by Economic Times last month. The breach led the board and shareholders to demand repayment of the Loan. Additionally, the share price had to be readjusted as it had been available for Rs 20 per equity share in the grey market, as told by an anonymous source who is familiar with the development.
Furthermore, current shareholders TPG and Temasek are leading the rights issue. According to a source, Ranjan Pai, the chairman of the Manipal Group who owns a stake in Manipal Hospital, will join the company board.
Let’s learn more about the company so potential investors can consider investing in its unlisted shares.
About The Company
PharmEasy is a digital healthcare platform in India that offers various services, including consultations, diagnostics tests, medicines, healthcare products, and information from trusted pharmacies, doctors, and diagnostic laboratories nationwide. It covers every habitable area of India.
The platform was founded in 2015 by Dharmil Sheth, an MBA graduate from IMT Ghaziabad, and Dr Dhaval Shah, an MBBS graduate from Rajiv Gandhi Medical College and an MBA graduate from XLRI Jamshedpur. They aimed to provide affordable and accessible healthcare to everyone through an online pharmacy.
Based on the RedSeer Report for the year ended March 31, 2021, they are India’s largest digital healthcare platform in terms of GMV of products and services sold. Their business is fully integrated and covers all stages of healthcare for consumers, providing comprehensive solutions.
- Provides access to digital resources, tools, and information for both illness and wellness.
- Offers tele-consultation services
- Diagnostic and radiology tests
- Deliver treatment protocols that involve the use of products and devices
PharmEasy’s unique abilities come from its custom-built proprietary technology, unified data platforms, supply chain capabilities, and extensive knowledge of the complex interplay between different sub-segments of India’s healthcare market. These capabilities set the company apart from the others.
PharmEasy provides value to all stakeholders in the healthcare industry, including:
- Different distribution channels: wholesalers, retailers, and chemists or institutions.
- Consultants, hospitals, and diagnostic and radiology labs are included in this category.
- The consumers.
- Companies operating in the pharmaceutical, nutraceutical, and medical device industries.
The Funding History Of PharmEasy
|March 2016||~34 Crores|
|March 2017||~104 Crores|
|April 2017||~13 Crores|
|February 2018||~13 Crores|
|September 2018||~350 Crores|
|September 2018||~2800 Crores|
|November 2019||~1650 Crores|
|April 2021||~2400 Crores|
|June 2021||~150 Crores|
About PharmEasy Business Model & Unlisted Shares
The business model of PharmEasy is uncomplicated and easy to understand. It simply links buyers, suppliers, and distributors. The buyers can choose from its range of services, including medicine, healthcare products, and diagnostic tests, from the application and website.
The company receives a commission of approximately 1-2% on the sale of medicines, earns from displaying advertisements of different pharmaceuticals, nutraceuticals, and other companies, and generates revenue from diagnostic tests. PharmEasy earned a revenue of Rs 5728 crore in FY2022 compared to Rs 2335 crore in FY2021.
Over the years, the company showed a positive growth rate, enticing retailer investors to buy PharmEasy unlisted shares. You can easily buy its pre-IPO shares using an online unlisted shares trading platform like Stockify.
Here are the details of PharmEasy pre-IPO stocks:
|Total Available Shares:||10000|
|Face Value:||₹ 1 Per Equity Share|
|Lot Size:||1000 Shares|
|Current Unlisted Share Price:||₹ 19.7522 Per Equity Share|
Why Is It Worth To Buy PharmEasy Unlisted Shares?
PharmEasy’s business model is simple and easy to understand. It connects buyers, suppliers, and distributors. Buyers can select various services from the app and the website, including medicines, health products, and diagnostic tests.
The company receives a 1-2% commission on the sale of drugs, earns by displaying advertisements of different pharmaceuticals, nutraceuticals, and other companies, and generates revenue through diagnostic tests. PharmEasy’s IPO price, opening, and closing dates have yet to be announced, and investors eagerly await to place their bets on its IPO.
The issuance of PharmEasy IPO may cause strong fluctuations in the price of PharmEasy unlisted shares. So if you want to diversify your investment portfolio, unlisted shares of PharmEasy can benefit you. You can easily plan your investment after analyzsing PharmEasy financial performance, price history, and other metrics.